GliaGen

GliaGen is a biotechnology company focused on developing first-in-class small molecule therapeutics for neurodegenerative and neurological disorders. The company's approach centers on modulating astrocyte metabolism, specifically targeting the glycogen phosphorylase enzyme to regulate energy supply to neurons. By focusing on the astrocyte-neuron lactate shuttle, GliaGen aims to provide neuroprotection and restore cognitive function in conditions such as Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The company's research is based on foundational work from the University of Texas at Austin. GliaGen is currently in the pre-clinical stage of development for its lead programs.